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Early and persistent activation of complement is considered to play a key role in the
pathogenesis of COVID-19. Complement activation products orchestrate a
proinflammatory environment that might be critical for the induction and maintenance of
a severe inflammatory response to SARS-CoV-2 by recruiting cells of the cellular immune
system to the sites of infection and shifting their state of activation towards an
inflammatory phenotype. It precedes pathophysiological milestone events like the
cytokine storm, progressive endothelial injury triggering microangiopathy, and further
complement activation, and causes an acute respiratory distress syndrome (ARDS). To
date, the application of antiviral drugs and corticosteroids have shown efficacy in the early
stages of SARS-CoV-2 infection, but failed to ameliorate disease severity in patients who
progressed to severe COVID-19 pathology. This report demonstrates that lectin pathway
(LP) recognition molecules of the complement system, such as MBL, FCN-2 and CL-11,
bind to SARS-CoV-2 S- and N-proteins, with subsequent activation of LP-mediated C3b
and C4b deposition. In addition, our results confirm and underline that the N-protein of
SARS-CoV-2 binds directly to the LP- effector enzyme MASP-2 and activates
complement. Inhibition of the LP using an inhibitory monoclonal antibody against
MASP-2 effectively blocks LP-mediated complement activation. FACS analyses using
transfected HEK-293 cells expressing SARS-CoV-2 S protein confirm a robust LP-
dependent C3b deposition on the cell surface which is inhibited by the MASP-2
inhibitory antibody. In light of our present results, and the encouraging performance of
our clinical candidate MASP-2 inhibitor Narsoplimab in recently published clinical trials, we
suggest that the targeting of MASP-2 provides an unsurpassed window of therapeutic
efficacy for the treatment of severe COVID-19.
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Coronaviruses (CoVs) are single-stranded RNA viruses causing
life threatening respiratory infection in humans and other
species. The CoV genome encodes four main structural
proteins, spike (S), membrane (M), envelope (E), and
nucleocapsid (N), as well as other accessory proteins that
facilitate replication and entry into cells. The transmembrane
bound spike protein (S), consists of two subunits S1 and S2 that
cover the surface of CoVs and serve as receptor binding entry
proteins for infection. The nucleocapsid protein complexes with
the viral RNA and plays a major role in viral replication as well as
viral pathogenesis. M and E are two transmembrane proteins,
which are responsible for viral assembly (1). In 2019, a pandemic
respiratory infection caused by corona virus was reported and
identified as coronavirus disease 2019 (COVID-19), the
etiological agent of which is a b-coronavirus called severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical
manifestation of SARS-CoV-2 infection include fever, cough,
fatigue, myalgia, and pneumonia, that may develop into acute
respiratory distress syndrome (ARDS), necessitating respiratory
support, as well as disseminated intravascular coagulopathy and
kidney failure (2, 3).
The complement system (CS) is an integral part of the innate
and the adaptive immune systems. The CS is composed of more
than 30 plasma and cell-resident components that form a first
defence-line against infection and provides an essential
scavenger system to eliminate injured, apoptotic or aberrant
cells. Complement activation products modulate inflammation
and direct the innate and the adaptive immune response. The CS
is activated via three pathways, which funnel into a shared
terminal activation route. The classical pathway (CP) is
initiated through the binding of a recognition subcomponent,
specifically complement component 1q (C1q). Two C1q-
associated serine protease zymogens, C1r and C1s, form a C1s-
C1r-C1r-C1s hetero-tetramer, which sits within the calix of the
C1q macromolecule. The C1r/C1s zymogen complex is
converted into active form when at least two arms of the C1q
macromolecule bind to the Fc region of immune complexes.
Activation of C1s leads to the cleavage of C4 to C4a and C4b,
with the latter binding to C2. C4b-bound C2 is then cleaved by
C1s to create the C3 convertase C4b2a, which cleaves the
abundant complement component C3 into the anaphylatoxin
C3a and the major fragment C3b (4). The Lectin pathway (LP) is
initiated by multimolecular pattern-recognition complexes that
bind to immune complexes and pathogen-associated molecular
patterns (PAMPs). Six different LP recognition subcomponents
can form LP activation complexes by binding dimers of three
different mannan-binding lectin-associated serine proteases
(i.e., MASP-1, MASP-2 and MASP-3). The recognition
subcomponents comprise multimers of homotrimeric chains,
which can bind directly to their cognate ligands present on
pathogens, or to aberrant glycosylation patterns on apoptotic,
necrotic, malignant, or damaged host cells (5, 6). The LP
recognition subcomponents in humans are: mannan-binding
lectin-2 (MBL-2), collectin-11 (CL-11), heterocomplexes ofFrontiers in Immunology | www.frontiersin.org 2CL-11 and CL-10 and three different ficolins (ficolins 1, 2, and
3), two of which can also form heterocomplexes (ficolins 2 and
3). MASP-2 is the key enzyme of the LP; only MASP-2 can cleave
C4 efficiently, whereas both MASP-2 and MASP-1 can cleave C2.
In the absence of MASP-2, complement can no longer be
activated by the LP activation route because the C3 and C5
convertase complexes C4b2a and C4b2a (C3b)n cannot be
formed (7, 8). In addition, MASP-2 was shown to cleave C3
directly, forming a novel C4-bypass activation route. This C4-
bypass route was shown to be important in the innate immune
defence (9). The alternative pathway (AP) fulfils its surveillance
function through a constant low-rate activation (C3 tick-over)
and provides an efficient amplification loop of C3 activation. The
C3 activation product C3b can bind to zymogen complement
factor B (FB), forming a complex that can in turn convert more
C3 into C3a and C3b if C3b-bound FB is cleaved by a serine
protease called FD (10).
Complement activation was reported to be associated with
development of acute respiratory distress syndrome (ARDS) and
respiratory failure during viral pneumonia (11, 12). A direct link
between complement activation and pathogenesis of Corona virus
infection was established using C3-deficient mice infected with
SARS-CoV. C3-deficient mice showed significantly less severe
respiratory inflammation, decreased infiltration of neutrophils
and inflammatory monocytes, and lower levels of cytokines and
chemokines in both the lungs and sera compared to wild-type
control mice (13). The involvement of complement-mediated
pathology and lung injury during SARS-CoV-2 infection was
revealed by a histopathological study of post-mortem biopsies
taken from COVID-19 patients. The presence of thrombotic
microangiopathies (TMAs) and the deposition of complement
activation products, including C5b-9, C3d, C4d and the LP
effector enzyme MASP-2 implied the involvement of LP and
CP activation in severe COVID-19 (14). In this study, we address
the involvement of the lectin activation pathway of complement
in the response against recombinant SARS-CoV-2 proteins and
which can trigger activation of the complement system.MATERIALS AND REAGENTS
Recombinant S and N proteins of SARS-CoV-2 expressed in
mammalian cell lines were purchased from R & D systems, UK.
The pEVAC plasmids expressing the coding sequences for S
protein were kindly provided by DIOSynVax Ltd Cambridge,
UK. Recombinant truncated MASP-2, containing the 2 CCP
domains and the serine protease domain, was expressed
previously described (9).
HG4, a monospecific fully humanised antibody against
MASP-2 that inhibits LP-mediated C4 cleavage was kindly
provided by Omeros Corporation, Seattle, USA. Pre-pandemic,
non-immune NHS, was pooled from 4 healthy donors. The mean
levels of key lectin pathway components in the pool were: MBL,
1.43µg/ml; FCN2, 2.9µg/ml; CL-11, 0.39µg/ml; and MASP-2,
0.4µg/ml.July 2021 | Volume 12 | Article 714511
Ali et al. Complement Activation via SARS-COV-2 ProteinsTransfection of HEK 293T Cells
HEK 293T cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% Foetal bovine serum
albumin (FBS), 2 mM glutamine and 10 U/mL penicillin, 10 mg/mL
streptomycin (Gibco). Cells were maintained in a CO2 incubator
at 37°C. HEK 293T cells were seeded in 6-well plates with cell
density of 1×106 cells/mL. Next day, cells were transfected with
1 mg of plasmid DNA for each well using the Fugene transfection
kit (Promega) according to the manufacturer’s protocol. Cells
transfected with empty pEVAC vector were used as a control.
48 hours after transfection, cells were harvested for flow
cytometer analysis.
FACS Analysis
Transfected HEK 293T cells were washed twice using Hank’s
balanced salt solution with C2+ and Mg2+ (HBSS++) and
resuspended in HBSS++ to a final concentration of 107 cell/mL.
106 cells were opsonised with 2.5% NHS in HBSS++ for 30
minutes at 37°C with or without 100 nM of HG4. Cells
transfected with empty vector were used as a negative control.
After opsonization, cells were washed twice with HBSS++ buffer,
and bound C3b was detected using FITC-conjugated rabbit anti-
human C3c (Dako). Fluorescence intensity was measured with
The Attune NxT Flow Cytometer (Invitrogen).
Solid Phase Binding Assays
Nunc MaxiSorp microtiter ELISA plates were coated with 10 mg/
mL of purified recombinant SARS-CoV-2 proteins S and N in
coating buffer (10 mMTris-HCl, 140 mMNaCl, pH 7.4). Control
wells were coated with 10 mg/mL mannan (a control for MBL
binding), 10 mg/mL zymosan (a control for CL-11 binding) or 10
mg/mL N-acetylated BSA (a control for L-ficolin binding).
Immune complexes formed by incubation of BSA with rabbit
anti-BSA were prepared. The ELISA plates were coated with 1
mg/mL BSA-anti-BSA immune complex as a control ligand for
C1q binding. The following day, wells were blocked for 2 hours at
room temperature with 250 mL of 1% (w/v) BSA in TBS buffer
(10 mM Tris-HCl, 140 mM NaCl, pH 7.4), then washed three
times with 250 mL of TBS with 0.05% Tween 20 and 5 mM
CaCl2 (wash buffer). Serial dilutions of serum in 100 mL of wash
buffer were added to the wells and the plates were then incubated
for 90 minutes at room temperature. Plates were washed as above
and bound proteins were detected using rabbit anti-human L-
ficolin, mouse anti-human CL-11 or mouse anti-human MBL
mAbs. HRP conjugated goat anti-rabbit IgG followed by the
colorimetric substrate (15).
Complement Deposition Assays
To measure C3 and C4 activation, Nunc MaxiSorp microtiter
plates were coated with 100 mL of 10 mg/mL mannan (Promega),
or 100 mL of 10 mg/mL SARS-CoV-2 proteins in coating buffer.
After overnight incubation, wells were blocked with 1% BSA in
TBS then washed with wash buffer. Serum samples were diluted
in BBS (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM
MgCl2, pH 7.4), starting at 5%, then added to the plates andFrontiers in Immunology | www.frontiersin.org 3incubated for 1.5 hours at 37°C. The plates were washed again,
and bound C3b or C4b were detected using rabbit anti-human
C3c (Dako) or rabbit anti-human C4c (Dako) followed by HRP
conjugated goat anti-rabbit IgG followed by the colorimetric
substrate TMB (15).
Complement Inhibition Assay
The activity of HG4 against MASP-2 was tested using C4b
deposition assay. 2.5% NHS containing different concentrations
of Hg4 in BBS were added to an ELISA plate coated with mannan
as previously described. Control wells received no antibodies. The
plate was incubated at 37°C for 15 min, then washed. Bound C4b
were detected using rabbit anti human C4c (Dako, Denmark)
followed by an HRP conjugated goat anti- rabbit IgG (Sigma,
USA). Bound antibody was detected using the Colorimetric
substrate TMB.
MASP-2 Binding Assay With SARS-CoV-2
Proteins
An ELISA plate was coated with 100 mL of 10 mg/mL SARS-CoV-
2 proteins in coating buffer. Wells were blocked with 1% BSA in
TBS then washed with wash buffer. Wells coated with BSA only
were used as a negative control. Serial concentrations of
recombinant MASP-2 in BBS, starting from 1mg/mL, were
added to the plate and incubated at room temperature. After 1
hour, the plate was washed andMASP-2 binding to SARS-CoV-2
proteins was detected using monoclonal antibodies against
MASP-2 followed by HRP-conjugated rabbit anti-human IgG
and the chromogenic substrate ELISA Colorimetric TMB
Reagent (Sigma). In a parallel experiment, 1mg of rMASP-2 in
100 mL BBS was incubated with wells coated with SARS-CoV-2
proteins for 1 hour at 37°C. After three washing steps using wash
buffer, 2.5 mg of purified C4 (Comptech, USA) in 100 mL BBS
were added to each well. Purified C4 added to wells coated with
BSA was used as a negative control. After 1-hour incubation at
37°C, supernatants were collected from each well and boiled with
4X SDS loading dye. C4 cleavage mediated via MASP-2 was
detected using SDS-PAGE and Coomassie bule staining under
reducing conditions.RESULTS
Recognition Molecules of LP Bind to
SARS-CoV-2 Proteins
A series of solid-phase binding ELISA were performed to identify
LP recognition molecules present in NHS that bind SARS-CoV-2
proteins. MBL, FCN2 and CL-11 bind to S and N proteins,
indicating possible activation of the complement system via the
LP. Interestingly, no C1q binding with SARS-CoV-2 proteins
was observed using non-immune NHS, suggesting that the
classical pathway is not activated in the absence of specific
antibody (Figure 1).July 2021 | Volume 12 | Article 714511
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Deposition on SARS-CoV-2
We measured complement C3b and C4b deposition on SARS-
CoV-2 proteins immobilised on microtiter plates. When serial
dilutions of pre-pandemic NHS were incubated on the plates,
there was a dose-dependent and saturable deposition of C3b and
C4b, indicative of LP activation, and comparable with the controlFrontiers in Immunology | www.frontiersin.org 4substrates. Essentially no C3b or C4b deposition was detected on
wells that were just blocked with BSA (p<0.01, 2-way ANOVA
vs. the control) (Figures 2A, B).
HG4 Inhibits LP Mediated C4b Deposition
The ability of the fully humanised monoclonal antibody HG4 to
inhibit LP functional activity was assessed using a C4b depositionA B
C D
FIGURE 1 | Binding of LP recognition molecules and C1q to SARS-CoV-2 proteins. A microtitre ELISA plate was coated with either S, N or control ligands (mannan
for MBL, N-acetyl BSA for FCN2, zymosan for CL-11 or immune complexes for C1q). Following incubation with blocking buffer and washing steps, serial dilutions of
NHS, starting at 5% were added to detect binding of LP recognition molecules and C1q from NHS to SARS-CoV-2 proteins. Human MBL (A), FCN2 (B), Cl-11 (C)
and C1q (D) were assayed by ELISA. A significant binding of LP recognition molecules to S and N proteins was clearly observed. No C1q binding to any of the viral
proteins was detected. Results are means of duplicates ± SD.A B
FIGURE 2 | Detection of C3b and C4b deposition on SARS-CoV-2 proteins. An ELISA plate was coated with SARS-CoV-2 proteins (S or N) or zymosan and
incubated with serial dilutions of NHS (starting at 5%) for 1 h at 37°C. C3b or C4b deposition were detected using antibodies against human C3c or C4c. High levels
of C3b (A) and C4b (B) deposition were observed on surface immobilised SARS-CoV-2 proteins.July 2021 | Volume 12 | Article 714511
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LP functional activity with an IC50 around 0.74 nM (Figure 3).
MASP-2 Binds Directly to N Protein and
Promotes MASP-2-Mediated C4 Cleavage
The ability of MASP-2 to bind directly to SARS-CoV-2 N protein
was tested using ELISA. A significant binding of rMASP-2 to N
protein was detected. To further confirm the functional
significance of this finding, ELISA wells coated with N-protein
or BSA were incubated with 1mg of rMASP-2 for 1 hour at 37°C.
After washing, 2.5 mg of purified C4 in BBS was then added to the
wells and incubated at 37°C. After 1 hour, the supernatant was
removed from the wells and the degree of C4 cleavage was
analysed using SDS-PAGE. C4 cleavage was observed when
purified C4 was incubated with N protein and rMASP-2 butFrontiers in Immunology | www.frontiersin.org 5not with BSA and rMASP-2. This experiment clearly showed that
MASP-2 binds to N protein and promotes LP-mediated C4
cleavage. Interestingly, inhibition of MASP-2 activity using
HG4 completely blocks LP-mediated C4 cleavage (Figure 4).
Evaluation of HEK 293 T Cells Expressing
SARS-CoV-2 Surface Proteins as a Model
to Detect COVID-19-Related Complement
Activation
To analyse complement activation on SARS-CoV-2 S protein
using a model that mimics the natural surface expression in cells
infected with SARS-CoV-2, we employed transiently transfected
HEK 293T cells. In this model, a transient high level of expression
of S protein on the surface of HEK 293T cells was achieved after
transfection with the mammalian expression vector pEVAC
containing the coding sequences for SARS-CoV-2 S protein.
Cells expressing viral protein were incubated with NHS or
pooled serum from convalescent patients, followed by detection
of bound human antibodies by incubation with goat anti-human
IgG Alexa fluor 647 antibodies. Fluorescence intensity was
measured with The Attune NxT Flow Cytometer (Invitrogen).
The level of anti-S protein antibody bound to HEK 293T cells was
approximately 100 fold higher when using convalescent human
serum compared to non-immune NHS (Figure 5). In a parallel
experiment, C1q binding to HEK293 cells expressing S protein
was not observed when using NHS (data not shown).
Inhibition of LP Impairs Complement C3b
Deposition on SARS-CoV-2 Proteins
To evaluate complement C3b deposition on the surface of HEK
293T cells expressing S protein, cells were incubated with 2.5%
NHS, and complement C3b deposition was detected using FACS
analysis. A significantly higher level of complement C3b
deposition was detected on cells expressing S protein compared
to non-transfected cells. Inhibition of lectin pathway using HG4FIGURE 4 | MASP-2 binds directly to SARS-Cov-2 N-protein and mediates complement C4 activation. (A) Microtiter plates were coated with 2.5mg/well N-protein
or BSA as a control. Residual binding sites were blocked using 1% BSA. Serial dilutions of rMASP-2 were added, and binding was detected using an anti-MASP-2
mAb. MASP-2 bound to the NP protein in a concentration-dependent and saturable manner (A). (B) In a parallel experiment, 1mg of rMASP-2 in barbital buffered
saline (BBS) was added to wells coated with NP or BSA. After 1 hr at 37°C, wells were washed and 1mg of purified human C4 was added to each well. After 1 hr
incubation at 37°C, the supernatant was collected and separated on SDS-PAGE. The results showed that rMASP-2 binds directly to NP and cleaves C4. Addition of
HG4 (a mAb that inhibits MASP-2) inhibited MASP-2 mediated C4 cleavage. Purified C4 was run on the gel as a control.FIGURE 3 | HG4 inhibits lectin pathway mediated C4b deposition. A
microtiter ELISA plate was coated with mannan and blocked with BSA.
Different concentrations of HG4 antibody were mixed with 2% NHS and
incubated on the plate. Bound C4b was detected using anti C4c antibodies.July 2021 | Volume 12 | Article 714511
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NHS (Figure 6).DISCUSSION
SARS-CoV-2 is an emerging virus with a very high infectivity that
causes life-threatening complications with mild to severe long-Frontiers in Immunology | www.frontiersin.org 6term morbidity and mortality, especially in patients with
underlying medical conditions (16). The immunopathology
differentiating mild from severe disease is not as yet sufficiently
well understood to identify the windows of therapeutic
opportunities for treatment (13, 17, 18). Excessive activation of
complement, initiated in part by viral invasion of endothelial cells,
causes collateral tissue injury (12). This work demonstrates that
the LP recognition molecules MBL, FCN-2 and CL-11 bind to SFIGURE 6 | Inhibition of LP impairs complement C3b deposition on SARS-CoV-2 surface proteins. HEK 293T cells expressing SARS-CoV-2 S protein were used.
Cells were incubated with 2.5% NHS with 100nM HG4 or an isotype control antibody at 37C for 30 min. Cells were washed and C3b deposition was detected using
rabbit anti human C3b followed by goat anti rabbit FITC labelled antibodies. A significant C3b deposition was detected on HEK 293T cells expressing S protein.
Inhibition of MASP-2 using HG4 significantly impairs complement C3b deposition on the surface of HEK 293T cells expressing S protein.FIGURE 5 | Transfection of HEK 293T promotes high levels of expression of SARS-CoV-2 surface proteins. The expression levels of S protein on the surface of
HEK 293 T cells were measured using serum from convalescent SARS-CoV-2 PCR positive patients or NHS (PCR negative) followed by anti-human IgG Alexa fluor
647 antibodies. Significant high levels of IgG binds to S were observed on the surface of HEK T293 cells.July 2021 | Volume 12 | Article 714511
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mediated C3b and C4b deposition. These findings clearly show
the activation of the LP on SARS-CoV-2 surface proteins and N
protein, confirming the central role of LP activation in the
immunopathogenesis of COVID-19. Tissue damage consistent
with complement-mediated microvascular injury has been
observed in the lung and/or skin of patients with severe
COVID-19, with significant deposition of the LP effector
enzyme MASP-2, a hallmark of profound activation of the LP
(14). Furthermore, extensive deposition of MASP-2 in the
capillaries and venules of small bowel thrombotic microvascular
injury in COVID-19 has also been reported, and endothelial
complement staining patterns colocalized with staining of SARS-
CoV-2 membrane and spike proteins (19). Our work also shows
direct binding of MASP-2 to the N protein of SARS-CoV-2 with
subsequent LP-mediated C4 cleavage into C4b and C4a,
confirming the previous finding of Gao et al., who reported
direct activation of MASP-2 on the SARS-CoV-2 N protein and
showed that MASP-2-deficient mice are protected from disease
(20). Since we used a truncated zymogen form of MASP-2,
containing the CCP1, CCP2 and serine protease domains, our
results also narrow down the N-protein binding site to these C
terminal domains. Our in vitro study confirms that inhibition of
MASP-2 blocks complement activation via the LP. Interestingly,
Narsoplimab, a fully humanized immunoglobulin gamma 4
(IgG4) monoclonal antibody against MASP-2 that inhibits LP
functional activity, has been used successfully in treatment of
critically ill, mechanical ventilation-dependent COVID-19
patients. Patients who received Narsoplimab recovered and
survived, demonstrating corresponding improvement/
normalization of laboratory markers of inflammation (21).
Many other complement inhibitors and anti-inflammatory
drugs have been re-purposed and evaluated in COVID-19
clinical trials but, to date, none of those other agents have
yielded a breakthrough in the treatment of severe COVID-19
(22–27). While vaccination is reducing hospitalisation, there is a
fear of possible reduction in the efficacy against the new variants,
which are responsible for severe cases of COVID-19 in younger
age groups. Therapeutic approaches utilizing passive immunity
(e.g., convalescent plasma, mono- and polyclonal antibodies),
have also been disappointing, demonstrating no meaningfulFrontiers in Immunology | www.frontiersin.org 7efficacy in severe COVID-19 and, possibly, adding to selection
pressure on SARS-CoV-2. There remains a need to pursue
aggressively and apply therapeutic strategies that block the
COVID-19 immunopathological events and endothelial
pathology, all of which appear to remain consistent across viral
variants, with the objective of increasing access to any effective
treatment(s) for acute as well as long-term post-COVID
pathology. As an alternative to tackling the virus itself,
protection from emerging new mutant viral strains could be
achieved by tackling the immune physiological events that turn
SARS-CoV-2 infections into generalised endothelial disease and
ARDS in those susceptible to moderate-to-severe COVID-19.
More research is needed to fully understand the disease processes
triggered by SARS-CoV-2 at a molecular level.
The present study provides new insights into the direct
triggers by SARS-CoV-2 at the protein level of LP activation in
the early phase of COVID-19, and the role of the LP in types of
long-haul COVID-19 are currently under investigation.DATA AVAILABILITY STATEMENT
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